Nuveen Asset Management LLC Cuts Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Nuveen Asset Management LLC cut its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 25.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 294,392 shares of the company's stock after selling 100,748 shares during the period. Nuveen Asset Management LLC owned about 0.23% of Humacyte worth $1,487,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Endowment Wealth Management Inc. increased its position in shares of Humacyte by 3.6% during the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company's stock worth $526,000 after purchasing an additional 3,590 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Humacyte by 18.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company's stock worth $138,000 after purchasing an additional 4,327 shares in the last quarter. Beacon Pointe Advisors LLC increased its position in shares of Humacyte by 33.3% during the fourth quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company's stock worth $101,000 after purchasing an additional 5,000 shares in the last quarter. Rhumbline Advisers increased its position in shares of Humacyte by 4.6% during the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company's stock worth $578,000 after purchasing an additional 5,005 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Humacyte by 25.3% during the fourth quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company's stock worth $132,000 after purchasing an additional 5,293 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company's stock.

Insider Transactions at Humacyte

In related news, CFO Dale A. Sander bought 20,000 shares of Humacyte stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average price of $1.53 per share, with a total value of $30,600.00. Following the purchase, the chief financial officer now owns 40,600 shares in the company, valued at $62,118. This represents a 97.09% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kathleen Sebelius purchased 50,000 shares of Humacyte stock in a transaction on Tuesday, April 8th. The shares were acquired at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the purchase, the director now owns 91,207 shares in the company, valued at approximately $120,393.24. This trade represents a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 83,993 shares of company stock valued at $118,224 in the last quarter. 5.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

HUMA has been the topic of several recent research reports. HC Wainwright initiated coverage on Humacyte in a research report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target on the stock. Wall Street Zen upgraded Humacyte from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Benchmark dropped their price target on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research report on Tuesday, May 13th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $11.71.

Humacyte Trading Down 1.1%

Shares of NASDAQ:HUMA traded down $0.03 during trading on Friday, hitting $2.59. 6,627,428 shares of the stock were exchanged, compared to its average volume of 3,812,784. The company has a fifty day moving average price of $1.79 and a two-hundred day moving average price of $3.22. The company has a market cap of $401.76 million, a PE ratio of -1.93 and a beta of 2.00. Humacyte, Inc. has a 12-month low of $1.15 and a 12-month high of $9.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. Equities research analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.